Immunservice

Developing variants of Interleukin-2 (IL-2) biologic medicines for cancer & viral infections

placeHamburg, Hamburg, Germany calendar_todayFounded 2006 groups7 employees language immunservice.com

Registered entities

Investor mix

6 investors on record; lead investors include BPO Capital, HTGF.

Investor typeCountShare
Venture capital233%
Other / undisclosed467%
Coming soon